Lifecycle Management

The Six-Month Shot That Broke HIV’s Business Model: Lenacapavir Is Rewriting Who Wins in a Market Everyone Thought Was Settled

Gilead's lenacapavir approval for HIV PrEP—100% efficacy, twice-yearly dosing—threatens daily-pill incumbents and signals a mechanism arms race across the...

By Moe Alsumidaie
May 4, 2026

The Semaglutide Patent Cliff Is a Threat to Everyone Who Thought Obesity Was a Premium Market

Trend Watch

The Semaglutide Patent Cliff Isn’t a Threat to Novo Nordisk — It’s a Threat to Everyone Who Thought Obesity Was a Premium Market

As semaglutide patents begin expiring and generic manufacturers in India and China gear up for mass production, the global...

By Moe Alsumidaie
April 9, 2026

Trend Watch

Biogen’s SPINRAZA High-Dose Approval Isn’t a Label Update — It’s a Lifecycle Defense Strategy in a Therapy Area That Is Running Out of Time

The FDA's approval of a high-dose nusinersen regimen looks like a routine label expansion. Read it as a commercial...

By Moe Alsumidaie
March 30, 2026

Trend Watch

The Efficacy Arms Race Has a New Ceiling — And Novo Nordisk Just Set It

Wegovy HD's FDA approval at 7.2 mg delivers 20.7% mean weight loss — but the real story isn't the...

By Moe Alsumidaie
March 20, 2026

Moe Alsumidaie

Chief Editor

The Six-Month Shot That Broke HIV’s Business Model: Lenacapavir Is Rewriting Who Wins in a Market Everyone Thought Was Settled

The Semaglutide Patent Cliff Isn’t a Threat to Novo Nordisk — It’s a Threat to Everyone Who Thought Obesity Was a Premium Market

Biogen’s SPINRAZA High-Dose Approval Isn’t a Label Update — It’s a Lifecycle Defense Strategy in a Therapy Area That Is Running Out of Time

The Efficacy Arms Race Has a New Ceiling — And Novo Nordisk Just Set It